Showcasing Global Utility of its QAPs at Point-of-Care Testing Conference MISSISSAUGA, Ontario, June 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator, manufacturer, and exporter, announces that it is attending and presenting at the 2nd Asia Pacific Conference on Point of Care Testing for Infectious Diseases, taking place in Bangkok, Thailand from 19 to 21 June, 2025 ("POC 2025"). At POC 2025, Microbix will be presenting a poster of results a ...

Company Overview - Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care [5] - The company's flagship offering, HealthTab™, aims to create the world's largest network of rapid testing devices in community pharmacies [5] Stock Options Announcement - The board of directors of Avricore has approved the granting of stock options for a total of 4,100,000 common shares at an exercise price of CAD $0.05 per share [1] - The options will vest quarterly starting from the date of grant and will expire 5 years from the grant date, contingent on the optionees remaining in their roles [2] HealthTab™ Product Details - HealthTab™ is a point-of-care testing solution that provides lab-accurate results from just a few drops of blood, with real-time data reporting [3] - The test menu includes up to 23 key biomarkers for chronic disease management, including diabetes and heart disease, and has recently added capabilities for bacterial and viral tests [3] HealthTab™ Network Model - The HealthTab™ network model enhances the role of pharmacists in primary care delivery and empowers patients to take control of their health [4] - It aims to reduce costs and waiting times while providing multiple revenue streams, including equipment leasing, direct access testing, and decentralized clinical trials [4]

VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or "Avricore") is pleased to report the appointment of Rodger Seccombe as CEO of the Company. Mr. Seccombe currently serves as Chief Technology Officer of Avricore and is the President and Co-Founder of its wholly owned subsidiary, HealthTab™ Inc. David Hall, Chairman of the board stated, "In his role as Avricore's CTO Rodger has been instrumental in the development of the Company's flagship Healt ...

VANCOUVER, British Columbia, May 01, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) reports on its year end 2024 and In the year ended December 31, 2024 revenue increased by 37% year over year to $4,785,711 and gross profit increased by 56% to $1,880,306.In the three months ended December 31, 2024 revenue increased by 5% year over year to $1,421,076 and gross profit increased by 18% to $589,930. “Launching and expanding HealthTab™ in North East London has been a mea ...